Freedom Biosciences
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Freedom Biosciences - overview
Established
2021
Location
San Francisco, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2021, Freedom Biosciences operates as a biotech company. The company was founded by its CEO Dina Burkitbayeva, CSO John Krystal, Hunter Bouchard, and Morgan Springer. In August 2022, Freedom Biosciences raised USD 10. 5 million in seed funding led by MBX Capital, PsyMed Ventures, The Yale Startup, and Village Global.
Freedom Biosciences develops and offers FREE001, which is a ketamine treatment that is used for the treatment of major depressive illness. The company offers various ketamine and psychedelic-based treatments to patients suffering from mental health disorders. The company plans to use the funds raised in August 2022 to advance its present lead ketamine program and an additional number of extra exploratory packages.
Current Investors
Village Global, MBX Capital, PsyMed Ventures
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Mental Health Services
Website
www.freedombio.co
Verticals
HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.